https://theorg.com/org/immunogen?person=james-stec
ImmunoGen | The Org
ImmunoGen, Inc. is a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer.
immunogen
https://www.benzinga.com/news/earnings/22/02/25834075/immunogen-q4-earnings-insights
Immunogen: Q4 Earnings Insights - Benzinga
Feb 25, 2022 - Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement....
immunogenq4earningsinsightsbenzinga
https://www.prnewswire.com/news-releases/critical-trade-alerts-for-ford-valero-humana-sourcefire-and-immunogen-released-by-investorsobserver-164573696.html
Critical Trade Alerts For Ford, Valero, Humana, Sourcefire, and ImmunoGen Released By...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, VLO, HUM, FIRE, and IMGN. (Photo:...
trade alertsfor ford
https://elifesciences.org/articles/97364/peer-reviews
Peer review in A modular platform to display multiple hemagglutinin subtypes on a single immunogen...
BOAS is a platform for building multivalent viral protein immunogens without a scaffold, such as a nanoparticle, to elicit broad influenza vaccine responses.
https://www.southampton.ac.uk/research/projects/structure-based-immunogen-design-ii-institute-for-protein-design
Structure based immunogen design II: Institute for Protein Design | University of Southampton
Structure based immunogen design II: Institute for Protein Design.
design iiuniversity ofstructurebasedimmunogen
https://theorg.com/org/immunogen/teams/leadership-team
ImmunoGen - Leadership Team | The Org
The Leadership Team at ImmunoGen is responsible for defining the strategic vision and direction of the company, overseeing the development and...
leadership teamimmunogen
https://www.fiercebiotech.com/biotech/debiopharm-buys-immunogen-adc-to-grow-cancer-pipeline
Debiopharm buys ImmunoGen ADC to grow cancer pipeline | Fierce Biotech
May 24, 2017 - Debiopharm has bought a phase 2 a
debiopharmbuysimmunogenadcgrow
https://theorg.com/org/immunogen/offices/hq
ImmunoGen - HQ | The Org
ImmunoGen's headquarters in Waltham, MA, United States
immunogenhq
https://www.southampton.ac.uk/research/projects/a-collaborative-network-for-the-analysis-of-hiv-1-immunogen-glycosylation
A Collaborative Network for the Analysis of HIV-1 Immunogen Glycosylation | University of...
A Collaborative Network for the Analysis of HIV-1 Immunogen Glycosylation.
collaborative networkfor the
https://www.biospace.com/immunogen-announces-conference-call-to-discuss-its-2022-operating-results
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - BioSpace
Feb 15, 2023 - ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company...
conference callimmunogenannounces
https://informaconnect.com/antibody-drug-conjugates/speakers/yelena-kovtun/
Yelena Kovtun - ex-ImmunoGen, USA | Antibody Drug Conjugates Speaker
Antibody Drug Conjugates // August 10, 2022 1 day digital event
antibody drug conjugatesyelenakovtuneximmunogen
https://www.businesswire.com/news/home/20231102139307/en/ImmunoGen-Announces-Webcast-of-Presentation-and-QA-at-Upcoming-Jefferies-London-Healthcare-Conference
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare...
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Comp...
https://www.biospace.com/immunogen-inc-announces-webcast-of-presentation-at-the-b-cowen-and-co-b-7th-annual-global-health-care-conference
ImmunoGen, Inc. Announces Webcast Of Presentation At The Cowen & Co. 7th Annual Global Health Care...
https://www.benzinga.com/general/biotech/24/06/39212271/abbvies-immunogen-acquired-elahere-meets-primary-goal-in-mid-stage-study-in-heavily-pretreated-ov
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated...
Jun 6, 2024 - AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.
https://www.lawinsider.com/contracts/e9n37p09pTl
IMMUNOGEN, INC. NON-QUALIFIED STOCK OPTION AGREEMENT by Immunogen Inc | Law Insider
IMMUNOGEN, INC. NON-QUALIFIED STOCK OPTION AGREEMENT filed by Immunogen Inc on November 15th, 2006
non qualified stock optionimmunogen incby lawagreementinsider
https://www.mdpi.com/2076-393X/9/7/750
Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen...
Stabilization of the HIV-1 Envelope glycoprotein trimer (Env) in its native pre-fusion closed conformation is regarded as one of several requirements for the...
https://theorg.com/org/immunogen/teams/marketing-and-sales-support
ImmunoGen - Marketing and Sales Support | The Org
The Marketing and Sales Support team at ImmunoGen plays a vital role in driving awareness and adoption of the company's antibody-drug conjugate therapies.
marketing and salesimmunogensupport
https://www.prnewswire.com/news-releases/why-investors-love-these-biotechs-stocks---immunogen-immunomedics-vanda-pharma-and-arrowhead-pharma-585021921.html
Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead...
/PRNewswire/ -- Lagging the market yesterday was the Biotech space, which continues to be challenged by costs, economic uncertainty, and policies....